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A Randomized Sham-Controlled Cross-Over Study on the 
Short-Term Effect of  Non-Invasive Cervical Vagus Nerve 
Stimulation on Spinal and Supraspinal Nociception in Healthy 
Subjects
Laura K. Alt, BSc; Katharina Wach; Eric J. Liebler, BSc; Andreas Straube, MD; Ruth Ruscheweyh, MD
Objective.—The aim of the present study was to test the effects of vagus nerve stimulation (VNS) on the descending pain 
inhibition, quantified by the nociceptive flexor (RIII) reflex and the conditioned pain modulation (CPM) paradigm, and on 
supraspinal nociceptive responses, assessed by pain intensity and unpleasantness ratings and late somatosensory evoked potentials 
(SEPs), in healthy subjects.
Background.—Non-invasive vagus nerve stimulation (nVNS) showed promising effects on headache and pain treatment. 
Underlying mechanisms are only incompletely understood but may include the activation of the descending pain inhibitory system 
and/or the modification of emotional responses to pain.
Methods.—Twenty-seven adult, healthy, and pain-free subjects participated in this double-blind cross-over study conducted 
at a university research center. They received 4  minutes of cervical nVNS or sham stimulation in randomized order. RIII 
reflexes, pain ratings, and SEPs were assessed before, during, and 5, 15, 30, and 60  minutes after nVNS/sham stimulation, 
followed by CPM testing. The primary outcome was the nVNS effect on the RIII reflex size. Three subjects were excluded 
after the preparatory session (before randomization), 1 subject was excluded after outlier analysis, leaving 23 for analysis.
Results.—RIII reflex areas were 917.1  ±  563.8  µV  ×  ms (mean  ±  SD) before, 952.4  ±  467.4  µV  ×  ms during and 
929.2  ±  484.0  µV  ×  ms immediately after nVNS and 858.4  ±  489.2  µV  ×  ms before, 913.9  ±  539.7  µV  ×  ms during and 
862.4  ±  476.0  µV  ×  ms after sham stimulation, revealing no differences between the immediate effects of nVNS and sham 
stimulation (F [3,66]  =  0.67, P  =  .574). There also were no effects of nVNS over sham on RIII reflex areas up to 60  minutes 
after nVNS (F [1.7,37.4]  =  1.29, P  =  .283). Similarly, there was no statistically significant effect of nVNS on pain intensity 
ratings and thresholds, RIII reflex thresholds, late SEP amplitudes, and the CPM effect, compared to sham. Pain unpleasant-
ness ratings statistically significantly decreased from 4.4  ±  2.4 (NRS 0-10) to 4.1  ±  2.5 during nVNS compared to sham 
stimulation (F [1,22]  =  8.74, P  =  .007), but there were no longer lasting effects (5-60  minutes after stimulation).
Conclusions.—The present study does not support an acute effect of nVNS on descending pain inhibition, pain intensity 
perception or supraspinal nociception in healthy adults. However, there was a small effect on pain unpleasantness during nVNS, 
suggesting that nVNS may preferentially act on affective, not somatosensory pain components.
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Recent studies have shown promising effects of 
non-invasive vagus nerve stimulation (nVNS) in acute 
and preventive treatment of migraine and cluster head-
ache1-5 and also in the treatment of other types of pain, 
eg, fibromyalgia.6 Consistent with the clinical effects 
on headache and migraine, VNS has been shown to re-
duce trigeminal nociception7,8 and cortical spreading 
depression.9 However, the exact mechanism by which 
VNS modulates nociception and pain perception is 
only incompletely understood. Animal research has 
suggested the involvement of descending pathways. As 
reviewed in Randich (1992),10 VNS can inhibit spinally 
mediated tail-flick responses and responses of noci-
ceptive dorsal horn neurons in rats. Lesion and local 
anesthetic injection studies suggest that this effect of 
VNS is mediated via the nucleus tractus solitarii and 
areas involved in the descending pain inhibitory sys-
tem such as the locus coeruleus and raphe nuclei.10 
From these areas, neurons descend to the spinal and 
trigeminal dorsal horn, where they inhibit nocicep-
tive transmission, resulting in reduced nociceptive 
input to the brain.11 VNS-induced activation of the 
locus coeruleus and raphe nuclei is also seen in human 
functional MRI.12,13 In summary, 1 possibility of how 
VNS may reduce pain is by activating descending pain 
inhibitory systems. In addition, supraspinal effects 
may also play a role. Curiously, while reported VNS 
effects in clinical pain are mostly analgesic, effects on 
human experimental pain perception are mixed,14-16 
which might in part be due to differences in stimula-
tion parameters. Bidirectional effects of VNS on pain 
intensity (increased by improved attention vs reduced 
by positive effects on mood) have been forwarded as an 
alternative explanation for inconsistent results, and it 
has been recommended that pain unpleasantness and 
mood are measured in addition to pain intensity to bet-
ter characterize the effect of VNS.7
Based on the above considerations, we hypothe-
sized that VNS (1) activates the descending pain inhibi-
tion and (2) reduces supraspinal nociception, possibly 
with a differential effect on pain unpleasantness vs 
pain intensity ratings.
The spinally mediated nociceptive flexor reflex 
(RIII reflex) is considered a measure of human spinal 
nociception,17,18 and activation of descending pain in-
hibitory pathways can be detected by the reduction of 
the reflex size.17,19 The CPM paradigm is an alternative 
measure, specifically assessing the “pain inhibits pain” 
aspect of pain inhibition, which is thought to include 
the activation of descending pain inhibitory path-
ways in humans.20 It assesses the effect of a noxious 
conditioning stimulus (eg, a cold water bath) on the 
pain perception of a heterotopic noxious test stimulus 
(eg, a heat pain stimulus). Late somatosensory evoked 
potentials (SEPs) reflect nociceptive, but in part also 
non-nociceptive activity in various brain regions21,22 
and can be used to estimate supraspinal nociception 
beyond pain ratings.23
Therefore, to test the above hypotheses, we  assessed 
the effect of cervical nVNS in healthy volunteers on (1) 
descending pain inhibition, as quantified by the RIII 
reflex and CPM paradigm and on (2) supraspinal no-
ciceptive responses, as quantified by pain intensity and 
Conflict of Interest: EL is an employee of electroCore, Inc, and receives stock ownership. The other authors declare no conflict of 
interest.
This work has been presented in the abstract form at the Congress of the German Pain Society in Mannheim, Germany, in 2018.
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pain unpleasantness ratings and by late SEPs. In addi-
tion, mood was assessed before and after VNS.
METHODS
Participants.—The study was conducted in accor-
dance with the Declaration of Helsinki and all pro-
cedures were approved by the local ethics committee 
(project number 17-464, approved on 10/AUG/2017) 
of the Ludwig-Maximilians-University Munich. Ex-
periments were performed between August 2017 and 
April 2018 at the University Hospital in Munich, 
Germany. A total of 27 participants were recruited by 
advertisements at the University Hospital. All partic-
ipants signed an informed consent form. They had to 
meet the following criteria: (1) ≥ 18 years old; (2) ade-
quate knowledge of German; (3) no psychiatric, neuro-
logical or internal diseases, including contraindications 
for performing a cold pressor test (immersion of the 
hand in painfully cold water, used as conditioning stim-
ulus within the CPM paradigm) such as Raynaud’s 
syndrome, coronary heart disease, or hypertension24; 
(4) no frequent or chronic pain like migraine, tension 
headache or chronic back pain > 5 days a month; (5) no 
contraindications for use of the gammaCore® device, 
including any active implant (eg, pacemakers or cochle-
ar implants), diagnosed stenosis of the carotid arteries, 
history of cervical vagotomy, and cervical stents or met-
al implants; (6) no alcohol or substance abuse and no 
regular use of drugs except for oral contraceptives and 
substitution of thyroid hormones; (7) not pregnant or 
breast-feeding; (8) no current or past use of nVNS.
Sample size: Given the unknown effect size of 
nVNS on descending inhibition, the sample size was 
based on our previous studies, successfully using RIII 
reflexes to detect the influence of various interventions 
on spinal nociception in samples of 14-22 subjects,25,26 
so we aimed at including 22 subjects.
Participant disposition: Of the 27 initially recruited 
subjects, 3 were excluded after the preparatory session 
because of large early, non-nociceptive (RII) reflex 
components interfering with RIII area quantification, 
because the electrical stimulus used to evoke the RIII 
reflex was too painful or the RIII reflex was too small 
(RIII area < 200 µV × ms). One subject was excluded 
after statistical outlier analysis (see section 2.9), leaving 
23 subjects for analysis. 25,26
Overview of the Procedure.—The study design was 
randomized, double-blind, sham-controlled, and 
cross-over. It consisted of 1 preparatory and 2 ex-
perimental sessions. During the preparatory session, 
participants completed the questionnaires and were 
familiarized with the electrical stimulation of the su-
ral nerve, pain intensity, and pain unpleasantness rat-
ings, and the CPM test. A total of 24 subjects participated 
in the 2 experimental sessions and were randomly (1:1) 
assigned to receive nVNS or sham stimulation first 
using the RAND() function in Microsoft Office Excel. 
The randomization sequence was generated by RR 
prior to the start of subject recruitment and was con-
cealed from the other investigators, including LA who 
enrolled the subjects and performed the experiments. 
Subjects were assigned to the respective random se-
quence based on the order of enrollment. All experi-
ments were performed by LA. Except for the type of 
stimulation, the 2 experimental sessions were identi-
cal and performed at least 7 days apart to avoid cross-
over effects (12.4 ± 2.2 days).
In the clinical research, nVNS statistically signifi-
cantly suppresses migraine pain at 30 and 60 minutes 
after stimulation.5 Therefore, we assessed nVNS effects 
during and up to 60 minutes after stimulation. An out-
line of the experimental sessions is shown in Figure 1. 
To allow for reflex stabilization, experimental sessions 
started with the assessment of RIII and pain thresh-
olds, followed by an 8-minutes run of suprathreshold 
electrical sural nerve stimulation (48 stimuli, applied 
every 8-12  seconds with an intensity ~170% of RIII 
threshold, intensity was kept constant within the ses-
sion, stabilization phase not shown in Figure 1). Then, 
at baseline, participants completed the positive and 
negative affect schedule (PANAS) and RIII and pain 
thresholds were assessed again. A 2-minutes run of 
suprathreshold electrical stimulation (12 stimuli) was 
performed and RIII areas and SEPs were obtained 
in response to each stimulus. Pain intensity and un-
pleasantness ratings were obtained at the end of the 
2-minutes block, rating the average of the preceding 5 
stimuli. This was followed by the intervention run, a 
10-minutes run of suprathreshold electrical stimula-
tion (60 stimuli), consisting of 2 cof reflex stabilization 
(not further analyzed), 2  minutes before nVNS/sham 
stimulation (“Pre”), 4  minutes during nVNS/sham 
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stimulation, which was applied first on the right side of 
the neck (“StimR,” 2 min), then on the left (“StimL,” 
2 min), followed by 2 minutes follow-up (“Post”). Like 
before, RIII areas and SEPs were assessed in response 
to each stimulus, and pain intensity and unpleasant-
ness ratings were obtained after each 2-minutes block. 
After 5  minutes nVNS/sham stimulation participants 
answered the PANAS again. At each of the follow-up 
time points (5, 15, 30, and 60  minutes after nVNS/
sham stimulation), RIII and pain thresholds were 
assessed followed by a 2-minutes run of suprathresh-
old stimulation (12 stimuli) to quantify RIII areas, SEP 
amplitudes, pain intensity, and unpleasantness ratings. 
Finally, the Conditioned Pain Modulation (CPM) par-
adigm and blinding check were performed. The study 
was conducted according to the original protocol.
The study was stopped after reaching a targeted 
sample size of 22. When subject 22 finished his last 
experimental session, there were 2 more subjects who 
already had started with the experiments, so these mea-
surements were finished, too.
Questionnaires.—As cognitive and affective factors 
(eg, depression and anxiety) are known to influence 
pain perception,27,28 German versions of the Pain 
Catastrophizing Scale (PCS),29,30 the Beck Depression 
Inventory (BDI),31,32 and the State-Trait Anxiety 
Inventory (STAI)33,34 were obtained and used to screen 
for potential clinically relevant levels of catastrophizing 
(cut-off > 3030) depressive symptoms (cut-off > 1335) 
during the preparatory session. There are no estab-
lished cut-offs for anxiety as measured by the German 
version of the STAI.
Fig. 1.—Outline of the experimental sessions. The study was randomized, double-blind, sham-controlled, and cross-over. Two 
experimental sessions were conducted on separate days. Subjects were randomly assigned to receive nVNS or sham stimulation in 
the first/second session. At baseline, participants completed the positive and negative affect schedule (PANAS). Then, RIII reflex 
and pain thresholds were obtained. Next, RIII reflex areas, somatosensory evoked potential (SEP) amplitudes, and pain intensity 
and unpleasantness ratings were obtained in response to 12 stimuli of suprathreshold electrical stimulation (intensity ~170% of 
RIII threshold). The intervention (nVNS/sham) was performed during a 10  minutes run of suprathreshold electrical sural nerve 
stimulation (60 stimulations). RIII areas, SEPs, pain intensity, and unpleasantness ratings were assessed during a stabilization block 
(not analyzed), and immediately before (pre), during, and after (post) the intervention. nVNS/sham stimulation was applied for a total 
of 4 minutes (StimR, 2 minutes on the right side of the neck, and StimL, 2 minutes on the left side of the neck). Five minutes after 
nVNS/sham stimulation, participants again rated the PANAS. During follow-up, RIII and pain thresholds were assessed followed 
by 2 minutes runs of suprathreshold electrical stimulations at 5, 15, 30, and 60 minutes after nVNS/sham stimulation. Finally, the 
Conditioned Pain Modulation (CPM) paradigm and blinding check were conducted. [Color figure can be viewed at wileyonlinelibrary.
com]
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To quantify the effects of nVNS on mood, partici-
pants answered the German version36 of the PANAS.37 
The PANAS is a self-report questionnaire consisting 
of 20 items (10 for positive and 10 for negative affect). 
Each item is rated on a 5-point scale from 1 (not at 
all) to 5 (very much) and the final positive and negative 
affect scores are formed by averaging item scores. It is 
known to be sensitive to detect short-term fluctuations 
in mood.37
RIII Reflex and SEP Recording.—During the ex-
periment, participants were sitting in a reclining chair 
with the right knee flexed at ~150°. Stimulation and 
recording of the RIII reflex and SEPs were performed 
with a Keypoint Portable EMG System (Natus, 
Planegg, Germany). The RIII reflex was evoked and 
recorded following established techniques.18,25 For 
stimulation and recording, skin sites were abraded 
with electrode gel and cleaned with 70% alcohol. A bi-
polar stimulation electrode (distance between the elec-
trodes was 23 mm) was placed at the retro-malleolar 
space over the sural nerve of the right lower limb. Each 
electrical stimulus consisted of a train of 5 impuls-
es of 1 ms duration separated by 4 ms (= 200 Hz). The 
electromyographic response was recorded using Ag/
AgCl surface electrodes placed on the ipsilateral short 
head of the biceps femoris muscle ~4-5 cm apart from 
each other. A ground electrode was fixed at the knee. 
Impedance was kept below 2 kΩ.
To record SEPs in response to painful sural nerve 
stimulation, standard EEG electrodes were placed at 
the vertex (Cz) with reference to the forehead (Fpz) 
as described previously.25 Impedance was kept below 
1 kΩ. Participants were asked to close their eyes, avoid 
eye movements, and relax their head, neck, and face 
muscles. After the preparatory session and the stabili-
zation run, where participants were reminded to relax 
and avoid eye movements, if  artifacts were evident in 
the SEP traces, satisfactory SEP recordings were ob-
tained throughout.
Electromyographic responses and EEG signals 
were amplified (up to 10,000 times) and band-pass 
filtered (20-1000 Hz for RIII recording; 0.5 to 500 Hz 
for SEP recording). RIII and SEP traces were saved 
for offline analysis from 90 ms before to 410 ms after 
stimulation.
Quantification of RIII and Pain Thresholds.—RIII 
and pain thresholds were assessed using procedures 
as described elsewhere.38,39 Briefly, participants re-
ceived electrical stimuli at the sural nerve separated by 
irregular intervals of 5 to 10 seconds to avoid stimu-
lus habituation. Starting from 2  mA, stimulus inten-
sity was increased in 2 mA steps until the RIII reflex 
appeared. An RIII reflex was detected if  the mean 
EMG response during the interval from 90 to 150 ms 
post-stimulation was at least 1.5 times the size of the 
standard deviation of the baseline period (65 to 5 ms 
before stimulation). Then, stimulus intensity was de-
creased and increased in 0.5 mA steps until the reflex 
was no longer detected or appeared again in response 
to 2 successive stimuli. The RIII threshold was defined 
as the average of the 4 intensities when the reflex disap-
peared for the first time, appeared for the second time, 
disappeared for the second time, and finally appeared 
again.38 The same procedure was used to quantify the 
pain threshold, using the appearance and disappear-
ance of the pain sensation as a marker.
Quantification of RIII Areas, SEP Amplitudes, and 
Pain Intensity and Unpleasantness Ratings.—For supra-
threshold stimulation, participants received a series of 
electrical stimuli with an intensity of ~170% of RIII 
threshold at pseudorandomized intervals of 8-12 sec-
onds to avoid stimulus habituation. To determine the 
RIII reflex area, RIII traces were baseline adjusted 
(baseline: 65 to 5 ms before stimulation), rectified, inte-
grated within the analysis window (90 to 150 ms after 
stimulation) and corrected for baseline activity by sub-
tracting the rectified integrated baseline area. RIII re-
flex areas were averaged over 3 consecutive stimuli for 
illustration and over 2-minutes blocks (12 stimuli) for 
analysis. SEP traces were rejected when the amplitude 
exceeded 100 µV.22 In addition, every SEP trace was vi-
sually inspected for artifacts. These procedures resulted 
in the rejection of 0-2 traces per 2-minutes block (each 
block consisted of 12 traces). Next, SEP traces were 
baseline adjusted (65 to 5 ms before stimulation) and 
averaged within each 2-minutes block. Averaged SEP 
traces consistently showed 4 components: (1) a positive 
peak around 45 ms (=P45),40 (2) a negativity around 
75-100 ms, likely corresponding to N100; (3) a nega-
tivity around 120  ms (=N120); (4) a broad positive 
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wave around 260 ms (=P260).21,22 In accordance with 
our previous procedure,25,41 we defined analysis win-
dows from 35-50 ms after stimulation to pick up the 
P45 peak, 70-100 ms for the N100, 100-150 ms for the 
N120, and from 280-350 ms for the P260 and measured 
mean amplitudes within those windows.
At the end of each 2-minutes block (after 12 stim-
uli), subjects rated the average pain intensity and pain 
unpleasantness of the electrical sural nerve stimula-
tion over the last 5 stimuli on the Numerical Rating 
Scale (NRS) from 0 to 10 (0  =  no pain/unpleasant-
ness, 10 = strongest pain/unpleasantness imaginable). 
Participants were asked to focus their pain intensity 
rating on the magnitude of pain, without taking into 
account emotional responses to pain such as aversion 
or fear, while focusing on the emotional aspects when 
giving the pain unpleasantness rating.
nVNS and Sham Devices.—There are different 
methods and devices to stimulate the vagus nerve in 
humans, ranging from implanted stimulators at the 
neck to non-invasive stimulation at the neck or at 
the vagal innervation area at the outer ear.5,42,43 For the 
purpose of the present study (to investigate the phys-
iological mechanisms underlying possible analget-
ic effects of VNS), we decided to use cervical nVNS 
with the GammaCore® device (Electrocore, Basking 
Ridge, USA) because several recent clinical studies 
demonstrate its efficacy in headache treatment.1,2,5 
The nVNS and sham devices (both provided by 
GammaCore®) looked identical and were marked 
with “A” and “B.” Both, the experimenter (LA) and 
participants were blinded to the type of stimulation. 
Whereas the nVNS device produced a proprietary 
low-voltage (maximum 24 V) electrical signal consist-
ing of 5 impulses each of 0.2 ms duration (5000 Hz), 
administered at 25 Hz, the sham device provided a low- 
frequency (0.1 Hz) biphasic electrical signal, designed 
by Electrocore to provide a sensation of stimulation 
without actually stimulating the vagus nerve. These 
correspond to the devices and stimulation parameters 
used in clinical studies.4,5 For nVNS/sham stimula-
tion, the experimenter placed the devices’ 2 stainless 
steel contact areas at the trigonum caroticum over the 
carotid pulse. To improve contact, a high conductivity 
contact gel (Parker Laboratories) was used. According 
to the procedure in previous clinical and basic research 
studies, stimulus intensity was adjusted until the stim-
ulation was perceived as strong but not unpleasant or 
painful.4,5,44 The exact stimulation intensity needed 
varies individually as a function of neck geometry and 
was not recorded in this or the previous studies. Stim-
ulation was applied for a total of 4 minutes (2 minutes 
on the right side of the neck, 2  minutes on the left), 
corresponding to the procedure used in the acute treat-
ment of migraine.5
CPM Paradigm.—The CPM paradigm was con-
ducted as an alternative measure of pain inhibition, 
including descending pain inhibition.20,45,46 Two iden-
tical painful “test” stimuli (contact heat for 30s) were 
applied at left volar forearm once before and once 
during a painful “conditioning” stimulus (cold water 
bath for 60 seconds). During the preparatory session, 
heat and cold temperatures were tailored individually, 
targeting a pain of about 6 on the NRS (0-10) for the 
heat stimulus (resulting in an average temperature of 
46.0 ± 1.5°C) and of at least 3 (after 30 seconds of ap-
plication) for the cold water bath (resulting in an aver-
age temperature of 8.8 ± 2.9°C). These predetermined 
temperatures were used during both experimental 
sessions. Heat stimuli were applied using the 3 × 3 cm 
ATS Thermode of the Pathway Pain & Sensory Evalu-
ation System (Medoc, Israel), using a baseline of 32°C, 
up and down ramps of 2°C per second and a time at tar-
get temperature of 30 seconds. Participants rated pain 
intensity on the NRS (0-10) every 10 seconds and the 
average of the 3 ratings was calculated. After a break of 
at least 5  minutes, participants put their open right 
hand up to the wrist into a styrofoam box filled with 
cold water at the target temperature for 60 seconds. Af-
ter the first 30 seconds of cold stimulation, the “test” 
(heat) stimulus was initiated and participants again rat-
ed heat pain intensity every 10 seconds. The CPM ef-
fect was quantified as the difference in the average heat 
pain ratings obtained before and during the cold water 
bath. A negative CPM effect indicated the activation of 
pain inhibition by the “conditioning” stimulus.
Statistical Analyses.—For statistical analyses, 
the Statistical Package of Social Sciences, version 22 
for Windows (IBM®, Armonk, NY, USA) was used. 
 Descriptive statistics are mean  ±  standard deviation 
unless indicated otherwise. Two-sided tests were used 
throughout and statistical significance was assumed at 
September 20201622
P < .05. Statistical testing for outliers was performed 
for all variables.
A 2-way repeated-measures analysis of variance 
(ANOVA) with the factors device (nVNS/sham) and 
time (Pre/StimR/StimL/Post) was performed to test for 
immediate effects of nVNS on RIII areas (primary out-
come, hypothesis: nVNS induces a larger reduction of 
RIII areas compared to sham stimulation (superiority 
testing)) and on SEP amplitudes (only Pre and Post), 
pain intensity, and unpleasantness ratings (secondary 
outcomes) during the 10-minutes suprathreshold sural 
nerve stimulation run.
To evaluate effects of  nVNS on RIII areas, SEP 
amplitudes, pain intensity, unpleasantness ratings, 
RIII and pain thresholds up to 60 minutes after stim-
ulation (secondary outcomes), 2-way repeated-mea-
sures ANOVA with the factors device (nVNS/sham) 
and time (baseline/5′/15′/30′/60  minutes follow-up) 
was conducted. The CPM effect on the test stimu-
lus pain intensity rating was assessed using a 2-way 
repeated-measures ANOVA with the factors device 
(nVNS/sham) and conditioning (before/during cold 
water bath). To test for changes in PANAS scores, 
2-way repeated-measures ANOVAs with the factors 
device (nVNS/sham) and time (baseline/5  minutes 
post) were conducted for both positive and negative 
affect scores. Violations of  sphericity were corrected 
using Greenhouse-Geisser adjustment. Effect sizes 
were quantified by partial eta squared. Significant 
differences were further analyzed using Bonferroni 
adjusted targeted post hoc 2-way repeated-measures 
ANOVAs or Bonferroni adjusted t tests for paired 
samples. The number of  comparisons that Bonferroni 
correction was applied for is indicated in the text. 
95% confidence intervals (CI) are reported for pair-
wise comparisons. McNemar Test was used for the 
blinding check.
nVNS or sham stimulation was applied in a ran-
domized order as detailed above. Including the order 
of nVNS/sham stimulation in the ANOVA did not 
reveal significant main effects of order or significant 
interactions with the order for any of these variables 
(see Supporting Tables S6 and S7), so for the ease of 
interpretation, we report the results without this addi-
tional factor.
A total of 24 subjects participated in nVNS and 
sham stimulation in a randomized order on 2 separate 
days as shown in Figure 1. Box plot analysis was con-
ducted for all outcome variables and revealed extreme 
values (exceeding the triple interquartile range of the 
sample) for change in RIII area at 30 and 60 minutes 
after stimulation in 1 subject. On visual inspection, this 
was due to a strong and continuous upward trend of 
the RIII reflex size starting 15 minutes after stimula-
tion, that was not seen in any other subject or in the 
other experiments of the same subject. We judged this 
most likely to be due to a technical problem with stim-
ulation (eg, shifting of the stimulation electrode) and 
excluded this subject. Thus, the final sample consisted 
of 23 participants.
RESULTS
Data from 23 subjects were included in the analy-
sis. Age, sex, and results of the PCS, BDI, and STAI 
questionnaires are shown in Table 1. Mean sural nerve 
stimulation intensity was 14.2  ±  3.9  mA during the 
nVNS session and 14.1 ± 4.1 mA for the sham session 
(t [22]  =  −0.21, P  =  .827, mean difference: −0.2  mA 
(95%CI: −1.6; 1.3). None of the participants spontane-
ously reported any adverse event of the nVNS or sham 
stimulation.
Please note that within this section, “significant” 
always means “statistically significant.”
Immediate Effects of nVNS.—The immediate ef-
fects of nVNS/sham stimulation were assessed during 
a 10-minutes experimental run performed immedi-
Table 1.—Characteristics of  the study population (n = 23)
Mean Standard deviation Range
Age (y) 27.1 1.3 18-45
% Female 60.9 - -
PCS 13.9 9.6 0-28
BDI 3.7 3.6 0-13
STAI state 33.9 7.8 24-52
STAI trait 33.5 7.6 21-54
No participant had questionnaire scores above the clinically 
relevant cut-off  values (see Methods).
BDI = Beck Depression Inventory; PCS = Pain Catastrophizing 
Scale; STAI = State-Trait Anxiety Inventory.
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ately before/during/after nVNS/sham as illustrated in 
 Figure 1. Results are shown in Figure 2 and Support-
ing Tables S1 and S3. In summary, there was no im-
mediate effect of nVNS vs sham stimulation on RIII 
reflex areas, SEP amplitudes, and pain intensity ratings. 
However, unpleasantness ratings decreased significant-
ly during nVNS stimulation compared to the imme-
diately pre/post-stimulation blocks and compared to 
sham stimulation.
In more detail, ANOVA on RIII reflex areas 
showed no main effects for device (F [1,22]  =  0.21, 
P = .649) or time (F [2.1,46.4] = 1.87, P = .164), and no 
significant interaction between both (F [3,66]  =  0.67, 
P =  .574). SEPs were available only for the pre and 
post-blocks because of  VNS/sham stimulation 
artifacts. ANOVA revealed no significant interaction 
between device and time for any of  the 4 SEP com-
ponents (F [1,22] = 0.11, P = .75 (P45), F [1,22] = 0.00, 
P  =  .977 (N100), F [1,22]  =  0.24, P  =  .630 (N120), 
and F [1,22] = 0.00, P =  .96 (P260)). There were also 
no significant main effects of  device or time (see 
Supporting Table  S3). For pain intensity ratings, 
there was no main effect of  time (F [2.1,46.5]  =  3.14, 
P = .050) or device (F [1,22] = 0.10, P = .751) and no 
interaction (F [1.9,42.7]  =  0.55, P  =  .576). For pain 
unpleasantness ratings, ANOVA revealed no main 
effect of  device (F [1,22] = 0.77, P = .390), but a signif-
icant main effect of  time (F [1.9,41.9] = 4.10, P = .025, 
η2p  =  0.157), and a significant interaction effect be-
tween device and time (F [3,66]  =  3.06, P  =  .034, 
Fig. 2.—Immediate effects of nVNS/sham. RIII reflex areas (A), SEP amplitudes (B), pain intensity (C), and unpleasantness ratings 
(D) in response to sural nerve stimulation before, during, and directly after nVNS or sham stimulation are illustrated. For RIII reflex 
areas, each data point illustrates a 30 seconds epoch, of 3 reflexes. SEP traces were averaged over 2 minutes and are available only 
during “Pre” (green) and “Post” (black) intervention blocks. Pain intensity and unpleasantness ratings were obtained every 2 minutes, 
as an average rating of the preceding 5 stimuli. Values are mean  ±  SEM. Statistical analyses revealed a statistically significant 
reduction of unpleasantness ratings during nVNS compared to sham stimulation, but no nVNS effects on the other parameters (see 
Results). [Color figure can be viewed at wileyonlinelibrary.com]
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η2p = 0.122). A post hoc test comparing the 2 nVNS 
(respectively sham) stimulation blocks combined 
with the pre and post-blocks combined showed 
that unpleasantness ratings were significantly lower 
during nVNS/sham stimulation than immediately 
before/after stimulation (F [1,22]  =  6.82, P  =  .016, 
η2p  =  0.237). Further subordinate testing showed a 
significant decrease of  unpleasantness ratings during 
nVNS (F [1,22] = 12.16, P =  .004, η
2
p = 0.356, mean 
difference: −0.4 (NRS 0-10) (95%CI: −0.6; −0.2), but 
not during sham stimulation (F [1,22] = 0.68, P = .838, 
mean difference: −0.1 (NRS 0-10) (95%CI: −0.3; 0.1); 
corrected for 2 comparisons). Unpleasantness ratings 
in the nVNS session were 4.5 ± 2.5 before/after and 
4.1  ±  2.5 during stimulation. In the sham session, 
they were 4.1 ± 2.3 before/after and 4.0 ± 2.5 during 
stimulation.
Effect of nVNS up to 60Minutes After Stimulation.— 
Effects of nVNS/sham stimulation were assessed 
during 2-minutes blocks at the baseline and 5, 15, 
30, and 60 minutes after stimulation (Fig. 1). Results are 
shown in Figure 3 and in Supporting Tables S2, S4, and 
S5. In summary, there was no effect of nVNS vs sham 
stimulation on RIII reflex areas, SEPs, RIII and pain 
thresholds and pain intensity and unpleasantness rat-
ings up to 60  minutes after stimulation compared to 
Fig. 3.—Effect of nVNS/sham stimulation up to 60 minutes after intervention. RIII reflex areas (A) and thresholds (B), pain intensity 
ratings (C) and thresholds (D), pain unpleasantness ratings (E), and SEP amplitudes (F) in response to sural nerve stimulation are 
illustrated at baseline and 5, 15, 30, and 60 minutes after nVNS/sham stimulation. Baseline SEP traces are marked in green, traces up 
to 60 minutes after nVNS/sham stimulation in black. Values are mean ± SEM. Statistical analyses revealed no significant differences 
between nVNS and sham stimulation (see Results). [Color figure can be viewed at wileyonlinelibrary.com]
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baseline. Pain intensity and unpleasantness ratings in-
creased over time, while RIII reflex and pain thresholds 
decreased over time.
In detail, for RIII reflex areas, there was no sig-
nificant main effect of device (F [1,22] = 0.25, P = .619) 
or time (F [2.0,44.5] = 2.70, P = .078), and no significant 
interaction (F [1.7,37.4] = 1.29, P = .283). For SEP am-
plitudes there was no significant interaction between 
device and time for P45 (F [4,88] = 1.91, P = .115), N100 
(F [4,88] = 0.83, P = .512), N120 (F [4,88] = 2.30, P = .065), 
and P260 (F [4,88] = 1.15, P = .340) and no main effects 
of device or time (Supporting Table S4). For both RIII 
and pain thresholds, ANOVA revealed a significant 
effect of time (F [4,88] = 22.08, P < .0001, η
2
p = 0.501 
(RIII); F [2.5,54.5] = 17.66, P < .0001, η
2
p = 0.445 (pain)) 
but no main effect of device (F [1,22] = 0.87, P = .362 
(RIII); F [1,22] = 0.23, P = .639 (pain)) and no interac-
tion between device and time (F [2.6,58.0] = 0.84, P = .467 
(RIII); F [4,88] = 1.10, P = .363 (pain)). Post hoc tests 
comparing each of the 4 time points to baseline (cor-
rected for 4 comparisons) showed that both RIII and 
pain thresholds decreased significantly over time (all 
P < .005, see Supporting Table S5). ANOVA on pain 
intensity ratings showed a significant main effect of 
time (F [1.5,33.8] = 9.35, P = .001, η
2
p = 0.298), but no 
main effect of device (F [1,22] = 0.04, P = .843) and no 
significant interaction (F [4,88] = 2.28, P =  .067). Post 
hoc t-tests revealed that pain ratings significantly in-
creased over time when compared to baseline (P < .05 
for all time points, see Supporting Table S5). For pain 
unpleasantness, ANOVA revealed a significant main ef-
fect of time (F [2.6,56.9] = 8.57, P < .0001, η
2
p = 0.280), 
but no significant main effect of device (F [1,22] = 0.41, 
P = .529) or interaction (F [4,88] = 0.77, P = .546). Post 
hoc t-tests showed significantly higher unpleasantness 
ratings at 60 minutes compared to baseline (t [22] = 4.14, 
P < .001, mean difference: 0.6 (NRS 0-10) (95%CI: 0.3; 
0.9) corrected for 4 comparisons), but not at the other 
time points (see Supporting Table S5).
Effect of nVNS on CPM.—The CPM test was per-
formed at the end of each experiment (~70  minutes 
after nVNS/sham stimulation). Shortly, there was a 
significant CPM effect, which was not significantly af-
fected by nVNS vs sham stimulation. Average test pain 
ratings before conditioning stimulation were 4.8 ± 1.8 
(nVNS session) and 5.3 ± 2.1 (sham session).  Average 
test pain ratings during conditioning stimulation 
were 3.8 ± 1.9 (nVNS) and 4.1 ± 1.9 (sham). ANOVA 
revealed a significant main effect of conditioning 
(F [1,22] = 18.21, P < .001, η
2
p = 0.453, mean difference: 
−1.1 (NRS 0-10) (95%CI: –2.0; –0.6), ie, a significant 
CPM effect amounting to a total of −20.3  ±  25.7% 
after nVNS and −18.1  ±  34.4% after sham stimula-
tion. No significant interaction effect (F [1,22]  =  1.09, 
P  =  .307) and significant main effect of device 
(F [1,22] = 2.12, P = .159, mean difference: −0.4 (NRS 
0-10) (95%CI: −0.9; 0.2) were found.
Effects of nVNS on PANAS Ratings.—The PANAS 
was assessed at baseline and 5 minutes after nVNS/sham 
stimulation (Supporting Table S2). In summary, there 
was a small but a significant decrease of positive affect 
over time, independent of nVNS or sham stimulation. 
ANOVA showed a significant effect of time on positive 
affect (F [1,22] = 8.23, P = .009, η
2
p = 0.272, mean dif-
ference: –0.2 (PANAS scale: 1-5) (95%CI: −0.3; −0.04) 
but not negative affect (F [1,22] = 0.20, P = .657, mean 
difference: 0.0 (95%CI: 0.0; 0.1). Participants’ positive 
affect score decreased over time from 2.6 ± 0.6 (base-
line) to 2.4 ± 0.7 (5 minutes). There was no significant 
interaction between device and time on subjects´ pos-
itive (F [1,22] = 0.17, P = .685) or negative affect score 
(F [1,22]  =  0.01, P  =  .913) and no significant main 
effect of device (F [1,22]  =  0.72, P  =  .404, mean 
difference: 0.1 (95%CI: −0.1; 0.3) (positive affect); 
F [1,22] = 0.14, P = .716, mean difference: 0.0 (95%CI: 
−0.2; 0.1) (negative affect)).
Blinding Check.—At the end of each experimental 
session, participants indicated whether they believed 
that they had received nVNS or sham stimulation. Af-
ter the sham and nVNS session, 43.5% and 60.9% of the 
subjects believed to have received true nVNS stimula-
tion, respectively, which was not significantly different 
(McNemar chi-square = 1.143, P = .285).
DISCUSSION
The main results of the present study are as fol-
lows. No activation of the descending pain inhibition 
could be demonstrated during and up to an hour after 
nVNS, as shown by a lack of effect of nVNS on the 
RIII reflex and the CPM effect. nVNS also did not af-
fect supraspinal nociceptive responses as quantified by 
pain intensity ratings and late SEPs. However, there 
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was a small but statistically significant reduction of 
pain unpleasantness ratings during nVNS compared to 
sham stimulation.
Effects of nVNS on Descending Pain Inhibition (RIII 
Reflex and CPM Paradigm).—nVNS had no effect 
on RIII reflex areas during and up to an hour after 
nVNS, or on RIII thresholds up to an hour after nVNS. 
In contrast, De Icco et al44 found a statistically signif-
icant increase of RIII reflex thresholds 5 and 30 min-
utes after nVNS compared to stimulation at the wrist 
in 10 healthy participants. Similar to our results, they 
also did not find an effect on RIII reflex areas. Differ-
ences in the present study may include using stimula-
tion at the wrist as control instead of sham stimulation 
at the neck. Although the sham stimulation at the neck 
has been explicitly designed to not activate the vagus 
nerve and has successfully been used in several clinical 
studies,3-5 it has recently been discussed if  it is indeed 
completely inactive as effects on EEG47 and the trigem-
ino-autonomic reflex48 has been reported. However, in 
our study, neither nVNS nor sham demonstrated a sta-
tistically significant antinociceptive effect compared 
to baseline.
Although the RIII reflex is a well-established 
marker of human spinal nociception17,18 that is sensi-
tive for the detection of changes in the descending pain 
modulation, eg, by stimulation of the periaqueductal 
gray23 and cognitive strategies,25,39 it also has its limita-
tions. These include a little contribution of C-fiber (vs 
Aδ-fiber) mediated nociception and the influence of 
interneuron and motor components.17,18,49 Therefore, 
we also investigated the effect of nVNS on the CPM 
effect, another paradigm used to assess pain inhibition, 
including descending pain inhibition.20 Consistent with 
the RIII reflex results, there was no effect of nVNS on 
CPM. This is similar to previous studies using different 
stimulation parameters and investigating other cohorts 
(eg, chronic pain patients), that also found no effect of 
VNS on CPM.16,50
When looking at the animal literature in more 
detail, cervical VNS effects on spinal nociception are 
mixed. While the inhibition of the tail-flick response 
predominates at strong VNS, facilitation is seen with 
less intense VNS. At the single dorsal horn neuron 
level, some neurons are consistently inhibited or consis-
tently facilitated by VNS, while many show a biphasic 
response, depending on VNS intensity.10 The present 
results suggest that at the clinically used nVNS stim-
ulation parameters, there is no net effect on descend-
ing pain modulatory pathways, at least not during and 
after a single short (4 minutes) bout of stimulation.
Effects of nVNS on Pain Intensity and Unpleasant-
ness Ratings.—There was no direct analgesic effect of 
nVNS as measured by pain intensity ratings and pain 
thresholds, both obtained in response to the electrical 
stimulation used to evoke the RIII reflex. Similarly, pre-
vious studies using auricular VNS also found no nVNS 
induced changes in heat pain thresholds,15 electrical 
pain thresholds,14 electrical pain intensity ratings,44 or 
pain evoked by laser stimulation.47 However, there is 
also evidence for pro-51 and anti-nociceptive effects of 
VNS52,53 in experimental pain testing.
These heterogeneous results have been hypoth-
esized to be due to contrary effects of nVNS on dif-
ferent psychological factors. Frangos et al12 proposed 
that nVNS increases attention toward pain and there-
fore may increase pain intensity ratings, while at the 
same time enhancing mood, thereby reducing the re-
action to pain. Consistently, there has been evidence 
from human fMRI studies that nVNS reduced the ac-
tivity of the medial pain system without altering pain 
thresholds.15 Positive effects of nVNS on mood and 
anxiety have also been reported.16,54 Indeed, we found 
that subjects estimated electrical stimulation of the 
sural nerve as less unpleasant during nVNS than im-
mediately before/after stimulation. Although this effect 
was small, it was not found during the sham session. 
However, there were no longer lasting effects of nVNS 
on pain unpleasantness (5-60  minutes after stimula-
tion). The PANAS, conducted at baseline and 5 min-
utes after stimulation failed to detect positive changes 
in subjects´ mood. This could argue for an immediate 
and short-lived effect of nVNS on pain unpleasantness 
independent from mood, but given the small size of 
the effect, this interpretation remains speculative and 
needs to be tested in further studies.
Effects of nVNS on SEPs.—Late SEPs have noci-
ceptive and non-nociceptive contributions.21,22 Con-
sistent with previous work,22,25 we identified 4 SEP 
components: (1) the P45, likely generated in prima-
ry somatosensory cortex,40 (2) the N100, that origi-
nates around the primary somatosensory cortex and 
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spreads to parietal association areas, (3) the N120, 
generated in the parietal operculum and insula, and 
(4) the P260, likely generated in multiple areas, 
including the anterior cingulate cortex, inferior pari-
etal cortex, and supplementary somatosensory asso-
ciation areas.21,22
In the present study, we did not find an effect of 
nVNS on any of these SEP components. To the best of 
our knowledge, this is the first study to investigate the 
effect of VNS on late SEPs. However, a previous study 
detected a statistically significant effect of nVNS over 
sham on laser-evoked P2 potentials (corresponding to 
the P260 component described above) during stimula-
tion, which was short-lived (almost back to baseline 
2 minutes after stimulation).47 In our hands, artifacts 
of the nVNS/sham stimulation prevented the analysis 
of SEPs during stimulation, so that a direct compari-
son with the previous study was not possible. A previ-
ous functional imaging study has shown the activation 
of several cortical regions, including prefrontal, ante-
rior insular, and anterior cingulate cortex during and 
up to 10 minutes after nVNS.12 While these are regions 
contributing to late SEP components (see above), it 
must be considered that SEPs represent responses of 
these regions to nociceptive (and also non-nociceptive) 
stimulation, not spontaneous activity. It should also 
be noted that the montage used in the present study 
(vertex vs frontal reference) was chosen to detect pain 
intensity reducing effects of nVNS and therefore to in-
crease the contributions of afferent nociceptive areas 
(primary somatosensory cortex, operculum, insula), 
while reducing the contribution of areas involved in 
pain modulation (anterior cingulate cortex, prefrontal 
cortex).
Strengths and Limitations.—Important strengths 
include the rigorous sham-controlled, double-blind 
cross-over design, and the use of a number of differ-
ent measures to assess descending pain inhibition (RIII 
 reflex areas and thresholds, CPM effect), pain (pain 
 intensity ratings and thresholds), supraspinal nocicep-
tive responses (SEPs), and affective components (pain 
unpleasantness and mood).
Limitations include the following. Firstly, we 
did not directly corroborate the successful stimula-
tion of  the vagus nerve. As nVNS mainly stimulates 
afferent vagal fibers,55 heart rates are not useful to 
confirm successful nVNS.16,56 However, previous 
 results strongly suggest that cervical nVNS indeed 
activates vagal afferents. For example, cervical nVNS 
statistically significantly activates vagal afferent pro-
jection areas, including the nucleus tractus solitarii12 
and, somatosensory potentials evoked by cervical 
nVNS (vagal SEPs) are comparable to those evoked 
by invasive and auricular VNS.57
Secondly, there are some possible limitations 
concerning the RIII reflex recording. Although 
we used irregular stimulation intervals  >  1  second 
(between 5 and 12  seconds), which have previously 
been described to minimize RIII reflex habitua-
tion,58,59 we cannot completely exclude that the 
relatively large number of  suprathreshold stimuli 
used during the course of  the experiment may have 
induced some habituation, possibly reducing the 
ability of  nVNS to induce further reflex reduc-
tion. However, RIII reflexes were stable over time 
and of  medium size, allowing modulation in both 
directions. An additional concern may be that electri-
cal sural nerve stimulation might have interfered with 
the action of  nVNS on descending pathways, as both 
were simultaneously applied to allow the assessment 
of  immediate nVNS effects. Both points are further 
differences to the previous study of  de Icco (2018)44 
which might have contributed to the divergent 
 results. Moreover, similar protocols have successfully 
demonstrated the effect of  psychological interven-
tions on the reflex size, proving that the RIII reflex 
can be modulated.26,43 In addition, although we mea-
sured the nVNS effect on RIII reflex thresholds and 
on suprathreshold RIII reflex sizes, we did not assess 
RIII temporal summation thresholds, which would 
have allowed quantifying the nVNS effect on the spi-
nal windup phenomenon. This would be an import-
ant follow-up project. Thirdly, although most of  the 
positive clinical results have been obtained in head-
ache, we used a paradigm assessing the activation of 
descending pain inhibition as assessed by the mea-
sures of  somatic (not trigeminal) nociception and 
pain perception. However, descending pain inhibi-
tory pathways are thought to lack somatotopic orga-
nization, affecting the entire body. Fourthly, to avoid 
interference with the experimental procedure (RIII 
reflex and SEP recording), pain and unpleasantness 
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ratings were measured at the end of  every 2-minutes 
block as an average of  the preceding 5 stimuli, entail-
ing a risk of  recall bias. Moreover, we studied healthy 
young participants, whereas clinical studies provid-
ing evidence for an analgesic nVNS effect investi-
gated chronic pain patients. The larger effect of  VNS 
in clinical vs healthy populations might be related to 
autonomic dysfunction in chronic pain and headache 
disorders.60,61 In addition, the present study only in-
vestigated the short term (up to 1 hour) effects of  a 
single short (2 × 2 minutes) bout of  nVNS. In clinical 
studies, both short-term effects of  a single stimula-
tion bout and long-term effects of  repeated stimu-
lation have been reported.1-5 Clearly, further studies 
are needed to clarify the relation of  nVNS effects on 
experimental pain in healthy volunteers to those on 
clinical pain in patients. Moreover, from the different 
methods and devices available for VNS in humans 
(invasive and non-invasive stimulation at the neck, 
stimulation of  the vagal innervation area at the outer 
ear42,43), we investigated only the effect of  cervical 
nVNS. It is not clear if  the results can be generalized 
to other forms of  VNS. Finally, as a general rule, the 
imprecision of  the results due to measurement error 
(eg, random error) has always to be considered.
CONCLUSIONS
The present results do not support an acute effect 
of nVNS on descending pain inhibition, pain inten-
sity perception or supraspinal nociception in healthy 
adults. However, there was a small effect on pain un-
pleasantness during nVNS, suggesting that nVNS may 
preferentially act on affective, not somatosensory pain 
components in the present setting. The present study 
adds to a body of literature showing little or inconsist-
ent effects of VNS on experimental pain in healthy 
subjects, while clinical studies have been encouraging 
regarding both acute and preventive effects in migraine 
and cluster headache. Maybe this means that VNS 
specifically targets nociceptive mechanisms of clinical 
pain, different from those that can be investigated by 
experimental pain testing.
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